Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Dietary intake and sources of sodium and potassium, and salt-related knowledge, attitudes, and behaviours among rural adults in China: a cross-sectional study.

Frontiers in nutrition·2026
Same author

Changes in the metabolome after treatment with canagliflozin in patients with type 2 diabetes.

Heart (British Cardiac Society)·2026
Same author

Sodium content of packaged foods and beverages in Nigeria: a cross-sectional comparative study with WHO global sodium benchmarks, Kenya, and South Africa.

Journal of nutritional science·2026
Same author

Assessing the implementation of national sodium reduction policies in Nigeria: an interim qualitative evaluation of stakeholder perspectives.

Frontiers in nutrition·2026
Same author

Lower-sodium, potassium-enriched salt substitution: An opportunity for improving blood pressure in Jamaica?

Public health in practice (Oxford, England)·2026
Same author

Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies.

Clinical kidney journal·2026

関連する実験動画

Updated: Feb 13, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K

カナグリフロジンと2型糖尿病における心不全: CANVASプログラムからの結果

Karin Rådholm1,2, Gemma Figtree, Vlado Perkovic2,3

  • 1Department of Medicine and Health Sciences, Division of Community Medicine, Primary Care, Faculty of Health Sciences, Department of Local Care West, County Council of Ötergötland, Linköping University, Sweden (K.R.).

Circulation
|March 13, 2018
PubMed
まとめ

カナグリフロジンは,2型糖尿病患者の心血管疾患による死亡や心不全による入院を大幅に減少させた. このナトリウム・グルコース・コトランスポーター2阻害剤の効果は,心不全の既往歴のある患者でより顕著であった.

キーワード:
SGLT2 阻害剤カナグリフロジン心不全ランダム化試験2型糖尿病

さらに関連する動画

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

関連する実験動画

Last Updated: Feb 13, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

科学分野:

  • 心臓病科
  • 内分泌学
  • 薬理学について

背景:

  • カナグリフロジンはナトリウム・グルコース・コトランスポーター2阻害剤で,心血管疾患のリスクを軽減するために研究されている.
  • 2型糖尿病 (T2DM) の患者では,心不全 (HF) と心血管疾患による死亡が重大な懸念事項である.

研究 の 目的:

  • T2DM患者における心不全と心血管疾患による死亡に対するカナグリフロジンの効果を評価する.
  • 心不全の初期経歴に基づいて,効果が異なるかどうかを評価する.

主な方法:

  • CANVASプログラムでは,カナグリフロジンまたはプラセボをランダムに割り当てられた高リスクT2DMの参加者10,142人が登録されました.
  • フォローアップ期間は平均188週間で,主なエンドポイントは心血管疾患による死亡またはHF入院でした.
  • サブグループ分析では,初期にHFを患っていたり,患っていなかったりした患者を対象とした.

主要な成果:

  • カナグリフロジンは,心血管疾患による死亡または入院の複合的なHFを減少させた (HR 0. 78; 95% CI 0. 67- 0. 91).
  • 死亡または入院したHF (HR 0. 70) と入院したHFのみ (HR 0. 67) も減少しました.
  • 統計的に有意な相互作用 (P=0. 021) は,心血管疾患による死亡または,心血管疾患の既往歴のある患者 (HR 0. 61) と,それのない患者 (HR 0. 87) の間で,心血管疾患による死亡または,入院に対する潜在的により大きな利益を示した.

結論:

  • カナグリフロジンは,様々なT2DMサブグループにおいて,心血管疾患による死亡やHF入院を減らす効果を示しています.
  • 薬の心血管上の効果は,心不全の発症歴のある患者でより顕著である可能性があります.